Shares in Celgene (Nasdaq: CELG) dropped almost 9% on Thursday, after one of Bristol-Myers Squibb’s (NYSE: BMY) largest shareholders revealed it would oppose the firms’ proposed $74 billion mega-merger.
Wellington Management said it thought the acquisition put too low a value on Bristol-Myers stock, involved too much risk, and would be too difficult to implement.
The investment fund also said that “alternative paths to create value for B-MS shareholders could be more attractive,” without specifying what those options might be.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze